Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GeneDx HoldingsWGS +3.30%65 Days Payable is 20.56 as of Jun. 2026, which is 64% below its 10-year median of 56.33. GuruFocus rates WGS with a GF Score™ of 65/100 and a GF Value™ of $73.77 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 190 Medical Diagnostics & Research companies, GeneDx Holdings ranks worse than 92.63% on this metric.
The historical rank and industry rank for GeneDx Holdings's Days Payable or its related term are showing as below:
WGS'
s Days Payable Range Over the Past 10 Years
Min: 13.07 Med: 56.33 Max: 91.21
Current: 13.07
During the past 7 years, GeneDx Holdings's highest Days Payable was 91.21. The lowest was 13.07. And the median was 56.33.
WGS's Days Payable is ranked worse than 92.63% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.075
vs WGS: 13.07
GeneDx Holdings's Days Payable
declined
from Jun. 2025 (27.81) to Jun. 2026 (20.56).
It may suggest that GeneDx Holdingsaccelerated paying its suppliers.
The historical data trend for GeneDx Holdings's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, GeneDx Holdings's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GeneDx Holdings Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, GeneDx Holdings's Days Payable distribution charts can be found below:
* The bar in red indicates where GeneDx Holdings's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
GeneDx Holdings's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GeneDx Holdings (WGS) has a Days Payable of 20.56 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on GeneDx Holdings and its competitors. This is 64% below median its historical median of 56.33. Over the past decade, GeneDx Holdings' Days Payable has ranged from 13.07 to 91.21. According to the industry distribution chart, GeneDx Holdings ranks #176 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 92.6%.
Is GeneDx Holdings' Days Payable too high?
GeneDx Holdings' current Days Payable of 20.56 is 64% below median its 10-year median of 56.33. Over the past 10 years, this metric has ranged from a low of 13.07 to a high of 91.21. The Medical Diagnostics & Research industry median Days Payable is 67.08. GeneDx Holdings' value of 20.56 is 69.3% below this industry median. Based on the distribution chart, GeneDx Holdings ranks #176 out of 190 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, GeneDx Holdings has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GeneDx Holdings' Days Payable compare to NEO and CDNA?
According to the Medical Diagnostics & Research industry distribution chart, GeneDx Holdings ranks #176 out of 190 companies for Days Payable. This places GeneDx Holdings in the lower half of its industry. The industry median Days Payable is 67.08. GeneDx Holdings' value of 20.56 is 69.3% below this benchmark. Historically, GeneDx Holdings' own Days Payable has ranged from 13.07 to 91.21 over the past decade. While the company's 10-year median is 56.33 vs. the industry median of 67.08, GeneDx Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 67.08, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GeneDx Holdings's current Days Payable of 20.56 is 69.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on GeneDx Holdings and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 67.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GeneDx Holdings's current Days Payable is 20.56, which is 64% below median its own 10-year median of 56.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GeneDx Holdings stock overvalued right now?
Based on GuruFocus' analysis, GeneDx Holdings (WGS) is currently considered Modestly Overvalued. The stock's GF Value™ is $73.77, compared to a current price of $90.32 — trading 22.4% above its estimated fair value. The current Days Payable is 20.56, which is 64% below median its 10-year median of 56.33 and 69.3% below the Medical Diagnostics & Research industry median of 67.08. GeneDx Holdings' overall GF Score™ is 65/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For GeneDx Holdings (WGS), the current Days Payable is 20.56 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GeneDx Holdings (WGS) Overvalued in 2026?
Based on GuruFocus' analysis, GeneDx Holdings stock appears to be overvalued.
The current stock price of $90.32 is trading 22.4% above its estimated GF Value™ of $73.77.
GuruFocus considers GeneDx Holdings to be Modestly Overvalued.
Key valuation signals for WGS:
Days Payable: 20.56 (64% below median its 10-year median of 56.33)
GF Value™: $73.77 vs. price of $90.32 (22.4% above fair value)
Industry Position: 69.3% below the Medical Diagnostics & Research median (#176 of 190)
No single metric tells the full story. See the WGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
65GF Score
Get the complete analysis for WGS
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WGS has been successfully added to your 
